Spyre Therapeutics Begins Phase 1 Trial with Initial Doses of SPY001, a New Long-acting anti-α4β7 Antibody, for Inflammatory Bowel Disease Treatment.

FDA has approved SKYRIZI® (risankizumab-rzaa) for treating ulcerative colitis, broadening AbbVie’s inflammatory bowel disease treatment options.

Sobi revealed that the European Commission has approved the Marketing Authorisation for ALTUVOCT™ (efanesoctocog alfa) for the treatment and prevention of bleeding episodes and perioperative prophylaxis in patients with haemophilia A.

KalVista Submits New Drug Application to FDA for Sebetralstat, the First Oral On-demand Treatment for Hereditary Angioedema.

Update on the CAPItello-290 Phase III study of Truqap combined with chemotherapy for advanced or metastatic triple-negative breast cancer.

NMD Pharma Gets FDA IND Approval to Start Phase 2 Study of NMD670 in US for Charcot-Marie-Tooth Disease.

Mozart Therapeutics Administers Initial Dose in Phase 1 Clinical Study of MTX-101 for Autoimmune Disease Therapy.

Zymeworks Receives FDA Approval for ZW171, a New Bispecific Antibody Targeting Mesothelin-related Tumors.

iTeos and GSK Launch Phase 3 GALAXIES Lung-301 Trial, Evaluating Belrestotug and Dostarlimab in Untreated, Inoperable Advanced/Metastatic PD-L1 Positive Non-Small Cell Lung Cancer.

Kira Pharmaceuticals Shares Encouraging KP104 Phase 2 PNH Trial Outcomes at 2024 EHA Congress, Highlighting Sustained Safety and Effectiveness.

A Biologics License Application for subcutaneous amivantamab was submitted to the U.S. FDA for people with non-small cell lung cancer with EGFR mutations.

The SKYLINE trial was a multicenter, randomized, and double-blind Phase 3 study that assessed the combination of soticlestat (TAK-935) with standard care against a placebo with standard care in patients suffering from refractory Dravet syndrome.